Kairos Pharma Ltd (KAPA) 財務

Kairos Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of novel and transformative drug therapies to treat cancer. The company is headquartered in Los Angeles, California and currently employs 1 full-time employees. The company went IPO on 2024-09-16. The firm is engaged in advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. Its therapy includes antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Its portfolio consists of seven drug therapies consisting of peptide and small molecule cancer immunotherapeutics KROS 101, 102, 201, 301 and 401 and therapeutic agents ENV 105 and 205. KROS 101 is a small molecule that targets the glucocorticoid-induced tumor necrosis factor ligand-related (GITR) ligand, a signal for T cell growth to remove a checkpoint barrier to fight a host of cancers. KROS 201 is a T cell therapy activated by dendritic cells to treat glioblastoma, a deadly and common brain cancer. ENV 105 drug seeks to address unmet medical needs in large markets of prostate and lung cancers.